Imidapril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Imidapril
Accession Number
DB11783
Type
Small Molecule
Groups
Investigational
Description

Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Imidapril Hydrochloride7NSF9GG1NU89396-94-1LSLQGMMMRMDXHN-GEUPQXMHSA-N
Categories
UNII
BW7H1TJS22
CAS number
89371-37-9
Weight
Average: 405.4449
Monoisotopic: 405.189985611
Chemical Formula
C20H27N3O6
InChI Key
KLZWOWYOHUKJIG-BPUTZDHNSA-N
InChI
InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
IUPAC Name
(4S)-3-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
SMILES
[H][[email protected]@](C)(N[[email protected]@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[[email protected]@]1([H])C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Imidapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Imidapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Imidapril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Imidapril is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Imidapril is combined with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Imidapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Imidapril is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Imidapril is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Imidapril is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Imidapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Imidapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Imidapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Imidapril.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Imidapril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Imidapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Imidapril.Approved, Withdrawn
AmbrisentanImidapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Imidapril.Experimental, Investigational
AmifostineImidapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Imidapril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Imidapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Imidapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Imidapril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Imidapril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Imidapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Imidapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Imidapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Imidapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imidapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Imidapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Imidapril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Imidapril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Imidapril is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Imidapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Imidapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Imidapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Imidapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Imidapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imidapril.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Imidapril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Imidapril is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Imidapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Imidapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Azapropazone.Withdrawn
AzathioprineImidapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Imidapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Imidapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Imidapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Imidapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Imidapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Imidapril.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Imidapril.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Imidapril is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Imidapril is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Imidapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Imidapril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Imidapril.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Imidapril is combined with Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Imidapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Imidapril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Imidapril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Imidapril.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Imidapril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Imidapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Imidapril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Imidapril.Approved, Investigational
BQ-123Imidapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Imidapril is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Imidapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Imidapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Imidapril is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Imidapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Imidapril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Imidapril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Imidapril.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Imidapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Imidapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Imidapril.Experimental
CafedrineImidapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Imidapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Imidapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Imidapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Imidapril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Captopril.Approved
CarbamazepineThe metabolism of Imidapril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imidapril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Imidapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Imidapril is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Imidapril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Imidapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Imidapril is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Imidapril.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Imidapril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Imidapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Imidapril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Imidapril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Imidapril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Imidapril is combined with Choline magnesium trisalicylate.Approved
CicletanineImidapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Imidapril.Approved, Investigational
CiprofloxacinImidapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Imidapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Imidapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Imidapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Imidapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Imidapril is combined with Clonixin.Approved
CloranololImidapril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Imidapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Imidapril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Imidapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Imidapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Imidapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Imidapril.Approved
CyclopenthiazideImidapril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Imidapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Imidapril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Imidapril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Imidapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Imidapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Imidapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Imidapril.Approved, Investigational
DelaprilImidapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Imidapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Imidapril.Investigational
DeserpidineImidapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Imidapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Imidapril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Imidapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Imidapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Imidapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Imidapril.Approved, Investigational
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Imidapril.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Imidapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Imidapril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Imidapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Imidapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Imidapril.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Imidapril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Imidapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Imidapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Imidapril is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Imidapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Imidapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Imidapril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Imidapril.Approved
DrospirenoneImidapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Imidapril is combined with Droxicam.Approved
DuloxetineImidapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Imidapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Imidapril.Approved
E-6201The risk or severity of adverse effects can be increased when Imidapril is combined with E-6201.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imidapril.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Imidapril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidapril.Approved
EndralazineEndralazine may increase the hypotensive activities of Imidapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Imidapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Imidapril.Approved
EpanololImidapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Imidapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Imidapril.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Imidapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Imidapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Imidapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Imidapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Imidapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Imidapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Imidapril is combined with Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Imidapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Imidapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Imidapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Imidapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Imidapril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Imidapril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Imidapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Imidapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Imidapril is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Imidapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Imidapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Imidapril is combined with Evening primrose oil.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Imidapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Imidapril is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Imidapril is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Imidapril is combined with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imidapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Imidapril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Feprazone.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Imidapril.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Imidapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Imidapril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Imidapril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Imidapril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Imidapril.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Imidapril is combined with Furosemide.Approved, Vet Approved
GarlicThe serum concentration of Imidapril can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Imidapril.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Imidapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Imidapril.Approved
GuanazodineImidapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Imidapril.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Imidapril is combined with Guanfacine.Approved, Investigational
GuanoclorImidapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzImidapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanImidapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Imidapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Imidapril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Imidapril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Imidapril.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Imidapril.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Imidapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Imidapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Imidapril.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Imidapril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Imidapril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Imidapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Imidapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Imidapril.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Imidapril.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidapril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Imidapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Indapamide.Approved
IndenololIndenolol may increase the hypotensive activities of Imidapril.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Imidapril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Imidapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Imidapril is combined with Indoramin.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Imidapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Imidapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Imidapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Imidapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Imidapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Imidapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Imidapril is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Imidapril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Imidapril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Imidapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Imidapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Imidapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Isradipine.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Imidapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Imidapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Imidapril is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Imidapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Imidapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Imidapril is combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Imidapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Imidapril is combined with Levobupivacaine.Approved, Investigational
LevodopaImidapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Imidapril is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Imidapril.Approved
LinsidomineImidapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Imidapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Imidapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Imidapril.Experimental
LofexidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Imidapril is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Imidapril is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Imidapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Imidapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Imidapril is combined with Lumiracoxib.Approved, Investigational
MacitentanImidapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Imidapril is combined with Magnesium salicylate.Approved
ManidipineManidipine may increase the hypotensive activities of Imidapril.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Imidapril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Imidapril is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Imidapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Imidapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Imidapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Imidapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Imidapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Imidapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Imidapril is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Imidapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Imidapril.Approved
MethoserpidineImidapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Imidapril is combined with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Imidapril.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Imidapril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Imidapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Imidapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Imidapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Imidapril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Imidapril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Imidapril is combined with Metoprolol.Approved, Investigational
MetyrosineImidapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Imidapril.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Imidapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Imidapril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Imidapril is combined with Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Imidapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Imidapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Imidapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Imidapril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Imidapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Imidapril is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Moxonidine.Approved, Investigational
MuzolimineImidapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Imidapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Imidapril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Imidapril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Imidapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Imidapril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Imidapril is combined with Naftifine.Approved
NaftopidilImidapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Imidapril is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Imidapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Imidapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Imidapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Imidapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Imidapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Imidapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Imidapril is combined with Niflumic Acid.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Imidapril.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Imidapril is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Imidapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitroprusside.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Imidapril.Approved
ObinutuzumabImidapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Imidapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Imidapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Imidapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Imidapril is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Imidapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Imidapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Imidapril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Imidapril is combined with Oxaprozin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Imidapril is combined with Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Imidapril is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Imidapril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Imidapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Imidapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Imidapril.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Imidapril is combined with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Imidapril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Imidapril.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Imidapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Imidapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Imidapril is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenelzine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Imidapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Imidapril.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Imidapril.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Imidapril is combined with Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Imidapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Imidapril.Approved
PinacidilPinacidil may increase the hypotensive activities of Imidapril.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Imidapril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Pipamperone.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Imidapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Imidapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Imidapril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Imidapril.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Imidapril.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Imidapril.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Imidapril is combined with Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Imidapril is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Imidapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Imidapril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Imidapril.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Imidapril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Imidapril is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Imidapril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Imidapril is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Imidapril.Approved
PTC299The risk or severity of adverse effects can be increased when Imidapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Imidapril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Imidapril.Approved
QuinineQuinine may increase the hypotensive activities of Imidapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Imidapril is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Imidapril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Imidapril.Approved
RescinnamineImidapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Imidapril is combined with Reserpine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Imidapril is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Imidapril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Imidapril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Imidapril.Approved
RisperidoneImidapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabImidapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Imidapril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Imidapril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Imidapril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Imidapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Imidapril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Imidapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Imidapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Imidapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Imidapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Imidapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Imidapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Imidapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Imidapril.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Imidapril is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Imidapril.Approved
SemapimodThe risk or severity of adverse effects can be increased when Imidapril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Imidapril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Imidapril is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Imidapril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Imidapril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Imidapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Imidapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Imidapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Imidapril.Approved, Investigational
SitaxentanImidapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Imidapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Imidapril is combined with Sodium Nitrite.Approved
Sodium phosphateImidapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Imidapril is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Imidapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Imidapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Imidapril can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Imidapril is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Imidapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Imidapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Imidapril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Imidapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Imidapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Imidapril.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Imidapril.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Imidapril is combined with Tamsulosin.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Imidapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Imidapril.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Imidapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Imidapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Imidapril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Imidapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Imidapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Imidapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Imidapril is combined with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Imidapril.Approved, Investigational
TetrahydropalmatineImidapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Imidapril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineImidapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Imidapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Imidapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Imidapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Imidapril is combined with Thioridazine.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Imidapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Imidapril is combined with Tiaprofenic acid.Approved
TiboloneTibolone may increase the hypotensive activities of Imidapril.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Imidapril.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Imidapril is combined with Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Imidapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Imidapril.Approved
TipranavirThe serum concentration of Imidapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Imidapril.Approved
TolazolineThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Imidapril is combined with Tolmetin.Approved
TolonidineImidapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Imidapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Imidapril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Imidapril is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Imidapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Imidapril.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Imidapril is combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Imidapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Imidapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Imidapril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Imidapril is combined with Triamterene.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Imidapril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Imidapril is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Imidapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Imidapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Imidapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Imidapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Imidapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Imidapril is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Imidapril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Imidapril.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Imidapril.Approved
UrapidilUrapidil may increase the hypotensive activities of Imidapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Imidapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Imidapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Imidapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Imidapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Imidapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Imidapril.Approved, Investigational
VincamineImidapril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineImidapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideImidapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Imidapril.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Imidapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Imidapril is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Imidapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Imidapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilImidapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Imidapril is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB41907
PubChem Compound
5464343
PubChem Substance
347828133
ChemSpider
4576628
BindingDB
50020400
ChEBI
135654
ChEMBL
CHEMBL317094
PharmGKB
PA452640
ATC Codes
C09AA16 — Imidapril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Microalbuminuria / Type 2 Diabetes Mellitus1
3Unknown StatusTreatmentHypertension,Essential1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.447 mg/mLALOGPS
logP0.74ALOGPS
logP-0.23ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.49ChemAxon
pKa (Strongest Basic)5.22ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area116.25 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity103.2 m3·mol-1ChemAxon
Polarizability42.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / N-acyl ureas / Fatty acid esters / Aralkylamines / Imidazolidinones / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Dicarboximides
show 9 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / N-acyl urea / Fatty acid ester / Ureide / Aralkylamine / Imidazolidinone
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:47 / Updated on December 01, 2017 17:31